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HARNESSING HUMAN POTENTIAL:
INDUCED PLURIPOTENT STEM CELL
PATENTABILITY UNDER THE
LENS OF MYRIAD
DEREK VAN DEN ABEELEN*
ABSTRACT
After the Supreme Courts decision in Assn for Molecular 
Pathology v. Myriad Genetics, previouslypatentable materials may
now be rejected as unpatentable subject matter, specifically be-
cause they cover naturalproducts. This presents a problem for
businesses performing adult stem cellresearch and development,
because stem cells exist in nature but pluripotencyin adult stem
cells does not. The United States Patent and Trademark Office
(USPTO)and federalcourts must recognize that these stem cells
are stillpatentable because there is human intervention that creates
a product that could not exist in nature on its own. Neither the
USPTO nor any federalcourts have yet reached the substantive
issue ofwhether stem cells are patentable post-Myriad.
Byrecognizing the patentabilityofadult stem cells, the USPTO
and federalcourts would allow research institutions to recoup
their substantialinvestment into the criticaladult stem cellfield,
while stillrespecting the standard ofpatentable subject matter dic-
tated in Myriad. This Note argues for retaining patentability of
adult stem cells in the face ofcertain future challenges to patentable
subject matter, at both the examination andappeals stages.
* J.D. Candidate, 2016, William & Mary Law School; B.S. in Cellular Biol-
ogy, 2007, University of California, Davis. I would like to thank my wonderful
wife, Veronica van den Abeelen, for constantly being my support and my
personal editor through the writing of this Note. I would also like to thank
the Business Law Reviews  executive editorial board for its help in editing 
this Note.
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INTRODUCTION
There is a heated debate about whether the medical use of
human embryonic stem cells is ethical. Many organizations view
such use as a destruction of human life, while other organiza-
tions see it simply as an advancement of essential human therapies.
Embryonic stem cells are cells taken from early-stage human
embryos, usually within four to five days after fertilization.1
These cells have the ability to differentiate into any type of cell
from the three germ layersan ability called pluripotency.2 This
pluripotency is incredibly important in researching new types of
therapeutic technology.3
This debate could easily be quelled if advances were made in
the development of adult stem cell research. There have been
some advances in this field, but each scientific success is met with
potential legal roadblocks. Companies looking to develop this tech-
nology may find that they have researched unpatentable material,
causing them to have invested time and money into a product
that is itself now unpatentable, and thus unprotected from com-
petitors. After the Supreme Courts decision in Assn for Molecular 
Pathology v. Myriad Genetics (Myriad), it is clear that natural
products are no longer patentable.
In accordance with this ruling, the United States Patent and
Trademark Office (USPTO) updated the Manual of Patent Exam-
ining Procedure (MPEP) to exclude naturally occurring sub-
stances from being patentable.4 While pluripotent embryonic stem
cells may not be patentable because they are naturally occurring,
induced pluripotent stem cells are not naturally occurring, and
1 NATL INSTS. OF HEALTH, STEM CELL BASICS: I. INTRODUCTION: WHAT ARE
STEM CELLS, AND WHY ARE THEY IMPORTANT?, http://stemcells.nih.gov/info
/basics/pages/basics1.aspx [https://perma.cc/JD4S-FVVL] [hereinafter STEM
CELL BASICS I].
2 Id.
3 Id.
4 See U.S. Patent and Trademark Office, Memorandum on 2014 Procedure
For Subject Matter Eligibility Analysis of Claims Reciting or Involving Laws
of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products
to Patent Examining Corps (Mar. 4, 2014) [hereinafter USPTO Guidance] (nat-
urally occurring substances are ones not markedly different from that found
in nature).
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are forced to transform into pluripotency through a complex chem-
ical process.5 Because this process is a step beyond a natural
process or product, creating pluripotent adult stem cells should
be patentable.
Part I of this Note will provide an overview of the science behind
stem cells, and will highlight the differences between embryonic
stem cells and adult stem cells. It will lay the groundwork of what
stem cells are, and how adult stem cells achieve pluripotency.
Part II will provide the statutory and common law basis for
how the USPTO and courts will interpret the law if an invention
is considered a natural product. It will identify the current stem
cell patent landscape, which developed before Myriadwas decided.
It will also review and analyze the Supreme Court cases that
speak to the patentability of natural products. It will look both at
how the Supreme Court approached natural products pre-Myriad,
as well as how this precedent applied to the facts in Myriad.
Part III will consider what approaches the USPTO and the
courts have taken post-Myriad when confronted with questions
of subject matter eligibility, specifically when a patent potentially
claims a natural product.
I. INTRODUCTION TO THE SCIENCE OF EMBRYONIC STEM CELLS AND
ADULT STEM CELLS AND THEIR DIFFERENCES
To understand the patentability of stem cells, it is necessary
to build a foundational understanding of what stem cells are,
and to dissect the difference between embryonic stem cells and
adult stem cells.
Stem cells are building block cells that have the ability to de-
velop into many different cells and organs throughout the life of
a human.6 Stem cells importance to research derives from the
fact that they are capable of dividing and renewing themselves
for long periods.7 This differs greatly from other cells found in
the body, such as mature muscle cells or blood cells, which do
5 NATL INSTS. OF HEALTH, STEM CELL BASICS: VI. WHAT ARE INDUCED
PLURIPOTENT STEM CELLS?, http://stemcells.nih.gov/info/basics/pages/basics10
.aspx [https://perma.cc/DL3U-CD73] [hereinafter STEM CELL BASICS VI].
6 STEM CELL BASICS I, supra note 1.
7 NATL INSTS. OF HEALTH, STEM CELL BASICS: II. WHAT ARE THE UNIQUE
PROPERTIES OF ALL STEM CELLS?, http://stemcells.nih.gov/info/basics/pages
/basics2.aspx [https://perma.cc/J444-MEMP] [hereinafter STEM CELL BASICS II].
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not normally self-replicate within the human body.8 Secondly,
stem cells retain the unique ability to become specialized cells
with specific functions, such as a brain cell or skin cell.9
Embryonic stem cells are stem cells derived from an egg that
is fertilized in vitro, meaning the egg is fertilized in a laboratory
environment or in a fertilization clinic.10 Despite the fact that
women donate these eggs and consent to their use in research,11
there are still many ethical concerns raised by numerous groups
regarding the use of fertilized embryos for research.12 Such ethi-
cal concerns, in turn, could result in hindering important research,
such as reduction in government funding towards embryonic stem
cell research.13
Adult stem cells, on the other hand, are not derived from em-
bryos.14 Instead, adult stem cells originate within mature tissues
and organs.15 These cells are still undifferentiated, like embry-
onic stem cells, and can both regenerate themselves and become
specialized cells.16 One of the most common uses of adult stem
cell therapy, bone marrow transplants, are not done within a
8 Id.; see also BRUCE ALBERTS ET AL., MOLECULAR BIOLOGY OF THE CELL
(4th ed. 2002), available at http://www.ncbi.nlm.nih.gov/books/NBK26853/
(For myoblaststhe building block cell of skeletal muscle fiber cells[o]nce 
differentiation has occurred, the cells do not divide and the nuclei never
again replicate their DNA.). 
9 STEM CELL BASICS I, supra note 1.
10 NATL INSTS. OF HEALTH, STEM CELL BASICS: III. WHAT ARE EMBRYONIC
STEM CELLS?, http://stemcells.nih.gov/info/basics/pages/basics3.aspx [https://
perma.cc/3HVD-H8K8] [hereinafter STEM CELL BASICS III].
11 Id.
12 CTR. FOR BIOETHICS & HUMAN DIGNITY, AN OVERVIEW OF STEM CELL
RESEARCH (Aug. 2008), https://cbhd.org/stem-cell-research/overview [https://
perma.cc/HRN6-FDPD] (stating that human embryos are human life, pointing to
verses in the Bible that require protecting unborn life).
13 See Kathleen Gilbert, Destroying Human Embryos Not OnlyUnethical,
but Unnecessary: Congressmen, LIFESITENEWS (Mar. 6, 2009), https://www
.lifesitenews.com/news/destroying-human-embryos-not-only-unethical-but-unnec
essary-congressmen [https://perma.cc/AQ3W-A4EB] (Pro-life congressional
members urged for the defunding of embryonic stem cell research, stating
that destruction of embryos is the destruction of human life.).
14 NATL INSTS. OF HEALTH, STEM CELL BASICS: IV. WHAT ARE ADULT STEM
CELLS?, http://stemcells.nih.gov/info/basics/pages/basics4.aspx [https://perma
.cc/44DV-K9RE] [hereinafter STEM CELL BASICS IV].
15 Id.
16 Id.
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lab.17 Unlike embryonic stem cells, however, adult stem cells are
limited in their ability to differentiate into different types of
cells.18 For example, neural stem cells are only able to differen-
tiate into neural cells (also known as neurons), and astrocytes
and oligodendrocytes (two types of cells essential to the central
nervous system).19
Companies and research laboratories look to harness the
possibilities of what stem cells can offer in numerous ways,20 but
one of the hurdles to the cells effectiveness is a laboratorys abil-
ity to differentiate the cells into the desired cells.21 For example,
scientists are still determining the signaling pathways that
cause stem cells to differentiate, which are necessary to create
the type of matured cells desired.22
One of the largest hurdles, specifically for adult stem cells, is
the fact that these cells need to first be genetically reprogrammed 
to an embryonic stem cell-like state through complex gene expres-
sion and other factors important to maintain a pluripotent stem
cellsteps that require human intervention.23 Researchers are
17 Id.
18 Id.
19 Id.; see also Astrocytes, NETWORK GLIA, http://www.networkglia.eu/en
/astrocytes [https://perma.cc/N8KW-Y8CJ] (stating that astrocytes are the 
most numerous and diverse neuroglial cells in the [central nervous system]); 
Oligodendrocytes, NETWORK GLIA, http://www.networkglia.eu/en/oligodendro
cytes [https://perma.cc/6QR4-NMRD] (remarking that oligodendrocytes are 
very well known as the myelin forming cells of the central nervous system). 
20 NATL INSTS. OF HEALTH, STEM CELL BASICS: VII. WHAT ARE THE PO-
TENTIAL USES OF HUMAN STEM CELLS AND THE OBSTACLES THAT MUST BE OVERCOME
BEFORE THESE POTENTIAL USES WILL BE REALIZED?, http://stemcells.nih.gov
/info/basics/pages/basics6.aspx [https://perma.cc/HC32-3C9K] [hereinafter STEM
CELL BASICS VII] (mentioning different uses of stem cells within laboratory
research, such as testing safety of new drugs, screening effectiveness of can-
cer drugs, and replacing destroyed tissues from diseases like macular degeneration
and diabetes); see also Catharine Paddock, Ability to repair cartilage with
stem cells steps closer, MED. NEWS TODAY (Mar. 4, 2015, 3:00 AM), http://www
.medicalnewstoday.com/articles/290298.php [https://perma.cc/4KX6-RDSC].
21 STEM CELL BASICS VII, supra note 20.
22 Id.
23 STEM CELL BASICS VI, supra note 5;see also UCLA ELI & EDYTHE BROAD
CTR. OF REGENERATIVE MED. & STEM CELL RESEARCH, INDUCED PLURIPOTENT
STEM CELLS (IPS), https://www.stemcell.ucla.edu/induced-pluripotent-stem-cells
[https://perma.cc/ZJ2S-WDXT].
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still discerning if there are any major clinical differences be-
tween embryonic stem cells and these induced pluripotent stem
cells (iPSCs).24 The existence of these challenges shows the
major need for further research and development in the stem cell
therapy field. Institutions and companies thus need an incentive
to invest time and money into such research, which can be pro-
vided through patent protection and licensing.25
It is clear that these stem cells, both embryonic and adult,
exist naturally in the human body.26 However, in order to induce
these cells to proliferate or differentiate, humans must use non-
natural processes and introduce non-natural products into the
cells.27 Embryonic stem cells already exist, under correct labora-
tory conditions, with the ability to proliferate and differentiate
into many different types of cells. Adult stem cells, however, re-
quire an extra step to become iPSCs, and then can both proliferate
and differentiate.28
II. STATUTORY AND SUPREME COURT RESTRICTIONS HAVE BARRED
PATENTABILITY FOR NATURAL PRODUCTS
A. StatutoryRequirements for Patentability
The United States Constitution explicitly gives Congress the
power to grant patent protection to inventors.29 Under 35 U.S.C.
§ 101, an inventor may receive a patent for any new and useful 
process, machine, manufacture, or composition of matter.30 This
section is what courts have looked to when interpreting whether
an invention is patentable subject matter.31 Section 112 sets the
requirements for specifications for patent applications:
24 STEM CELL BASICS VI, supra note 5.
25 See Rebecca S. Eisenberg, Patents and the Progress ofScience: Exclusive
Rights and ExperimentalUse, 56 U. CHI. L. REV. 1017, 102426 (1989); see
generally Katherine E. White, Preserving the Patent Process to Incentivize
Innovation in GlobalEconomy, 13 SYRACUSE SCI. & TECH. L. REP. 27 (2006).
26 See STEM CELL BASICS I, supra note 1.
27 See STEM CELL BASICS VI, supra note 5.
28 See id.
29 U.S. CONST. art. I, § 8, cl. 8 (Congress has the power to promote the Prog-
ress of Science and useful Arts.). 
30 35 U.S.C. § 101 (2014).
31 See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
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The specification shall contain a written description of the in-
vention, and of the manner and process of making and using
it, in such full, clear, concise, and exact terms as to enable any
person skilled in the art to which it pertains, or with which it
is most nearly connected, to make and use the same, and shall
set forth the best mode contemplated by the inventor or joint
inventor of carrying out the invention.32
Therefore, a person applying for a patent must sufficiently describe
the product or process. After reviewing the patent application, the
USPTO can choose to grant a patent if the application fully de-
scribes a patent that is novel, useful, and non-obvious.33
In 2011, Congress passed the Leahy-Smith America Invents
Act (AIA), which created new changes and additions to the patent
system.34 Though some changes were procedural, such as changing
the system from a first-to-invent system to a first-to-file system,35
the AIA also added a section stating that [n]otwithstanding any 
other provision of law, no patent may issue on a claim directed
to or encompassing a human organism.36 Though they did not
specifically identify natural products of humans, Congress did indi-
cate here that human organisms themselves should not be claimed
as patentable. However, the issue is determining to what extent
an invention is considered a human organism. More specifically,
the question is whether an invention that encompasses a small
component of a human organismhair, organs, or, as is relevant
to this Note, stem cellsis still considered a human organism. 
Prior to Myriad, there had been no designations in the MPEP
stating whether natural products could or could not be patented,
32 35 U.S.C. § 112(a) (2014).
33 Id. § 101 (stating that a patent may be obtained for any new and useful 
process, machine, manufacture, or composition of matter); see also id. § 102(a)
(2014) (reciting the novelty requirement); id. § 103 (2014) (A patent for a claimed 
invention may not be obtained ... if the ... claimed invention as a whole would have
been obvious before the effective filing date of the claimed invention to a person
having ordinary skill in the art to which the claimed invention pertains.). 
34 Nathan Hurst, How the America Invents Act WillChange Patenting For-
ever, WIRED (Mar. 15, 2013, 6:30 AM), http://www.wired.com/2013/03/america
-invents-act/ [https://perma.cc/QNY6-FAQ6].
35 Id.
36 Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 33(a), 125 Stat.
284, 340 (2011). Section 33(a) was later listed under the notes section, spe-
cifically for limiting the issuance of patents, under 35 U.S.C. § 101.
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which may be because no statutory requirement for excluding
natural products exists. It took a number of Supreme Court cases
to shape patentability standards.
B. The Common Law HistoryBefore Myriad
Over the years, the Supreme Court has heard cases that deal
with the subject matter of patents. The Court first clarified that
even if certain materials such as naturally occurring gases or
chemicals are natural products, they can create subject matter
that falls within the scope of patentability when the products
are combined.37 The Court believed that Congress envisioned a
broad scope when writing patent laws.38 The Court, however, did
specify that certain types of subject matter could not be patented,
mainly because they were not considered new and useful.39 These
exceptions to patentable subject matter were laws of nature, 
physical phenomena, and abstract ideas.40 Reasons for not al-
lowing people to patent such subject matter mainly point to the
idea that the grant of a patent might tend to impede innovation
more than it would tend to promote it.41 The Court, however, did
recognize that an overly broad interpretation of the exceptions
would hinder the ability of people to create new, useful, and non-
obvious subject matter.42
37 Diamond v. Chakrabarty, 447 U.S. 303, 308 (1980) ([C]omposition of 
matter has been construed consistent with its common usage to include all 
compositions of two or more substances and ... all composite articles, whether
they be the results of chemical union, or of mechanical mixture, or whether
they be gases, fluids, powders or solids. (citation omitted)). 
38 Id.
39 Bilski v. Kappos, 561 U.S. 593, 594 (2010) (While not required by the 
statutory text, these exceptions are consistent with the notion that a patentable
process must be new and useful.). 
40 Id. (citing Chakrabarty, 447 U.S. at 309); see also Gottschalk v. Benson,
409 U.S. 63, 67 (1972) (Phenomena of nature, though just discovered, mental 
processes, and abstract intellectual concepts are not patentable, as they are
the basic tools of scientific and technological work.). 
41 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289,
1293 (2012).
42 Id. (recognizing that too broad an interpretation of this exclusionary 
principle could eviscerate patent law. For all inventions at some level embody,
use, reflect, rest upon, or apply laws of nature, natural phenomena, or ab-
stract ideas.). 
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An early Supreme Court case concerning laws of nature was
Funk Bros. Seed Co. v. Kalo Inoculant Co.43 Here, the Court re-
viewed the patentability of two naturally occurring types of bac-
teria mixed together into one supposedly patentable culture.44
The claims did not cover a selection or testing process of the
strains, but simply the culture itself.45 The Court found that the
cultures benefitthe mixture of bacteria could be broadly used 
in legume farming without harming the other species of bacteria
in the mixturewas something that could not be considered
patentable because this characteristic already existed in nature,
and there was no inventive step involved.46
Diamond v. Chakrabartyclarified the scope of FunkBros. Seed
Co., and is one of the most relevant cases to stem cells before
Myriad.47 In this case, the Court considered whether a genetically
engineered bacterium capable of breaking down crude oil could
be considered patentable.48 No naturally occurring bacteria had
this ability, but the patent examiner rejected the inventors 
claim because the claims were based on a living thing, which
was considered unpatentable under 35 U.S.C. § 101.49 The Court
found that the examiners conclusion was erroneous, and instead
determined that this organism fell into the scope of a manufac-
ture or composition of matter, which § 101 provides is patent-
able.50 The Court cited Congresss intention to allow an inventor 
to obtain a patent for a product that was based on a natural
product or process.51 This bacterium exhibited markedly differ-
ent characteristics from any found in nature and one having the
potential for significant utility.52
43 333 U.S. 127 (1948).
44 Id. at 130.
45 Id.
46 Id. at 13132 ([A] product must be more than new and useful to be pat-
ented; it must also satisfy the requirements of invention or discovery.). 
47 447 U.S. 303 (1980).
48 Id. at 30506. 
49 Id.
50 Id. at 310.
51 Id. at 312 (citing S. Rep. No. 71-315, at 68 (1930); H.R. Rep. No. 71-1129, 
at 79 (1930)) ([Congress] explained at length its belief that the work of the 
plant breeder in aid of nature was patentable invention.). 
52 Id. at 310.
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This case is highly relevant to the fact that genetic engineer-
ing of a cellular organism is considered to be patentable. iPSCs
are similar to the genetically engineered bacterium in Chakrabarty
because each cell does not necessarily naturally exist in the
world.53 The bacterium in Chakrabartycontained a plasmid, cre-
ating an organism that had never been seen in nature.54 Like-
wise, an adult stem cella natural productthat is induced 
into pluripotency is not natural.55 Though the cell itself may
grow into a tissue that is truly natural, such as a patch of skin
or section of liver, that cell would not have come into existence
without a human beings inventive step.56
As of the writing of this Note, there has been no significant
litigation regarding the validity of patents for stem cells. Of the
recent litigation that has occurred, these cases involved the is-
sue of whether a researcher used the correct term of induced 
pluripotent stem cells in his patent application57 or whether the
Patent Trials and Patent Appeals Board was correct in affirming
the patentability of claims regarding stem cells.58 However, these
cases were simply struck down due to lack of standing.59
C. Patents on Stem Cells Issued Before Myriad
There are a number of stem cell patents that the USPTO
granted that are still valid. One of the most prominentand 
53 STEM CELL BASICS VI, supra note 5.
54 Chakrabarty, 447 U.S. at 305.
55 See supra note 23 and accompanying text.
56 Id.
57 See, e.g., Xu v. Yamanaka, No. 13-CV-3240, 2014 U.S. Dist. LEXIS
11772, at *2 (N.D. Cal. Jan. 30, 2014) (focusing more on state law claims made
by the plaintiff rather than federal claims relating to patentability).
58 Consumer Watchdog v. Wis. Alumni Research Found., 753 F.3d 1258
(Fed. Cir. 2014).
59 Xu, 2014 U.S. Dist. LEXIS 11772, at *1314 (finding that the plaintiff 
had not suffered an injury in fact); see also Consumer Watchdog, 753 F.3d at
126263. Consumer Watchdog attacked WARFs patents as invalid, but the 
court ruled that Consumer Watchdog had not shown it had sustained a
particularized, concrete interest in the patentability of the [WARF] patent, 
or any injury in fact. Id. at 1263. Unfortunately, the court did not rule on
whether the patent was valid, but concerned itself more with the issue of
standing. Id. The Supreme Court recently denied the writ of certiorari re-
garding this case, and thus Consumer Watchdog will have to find another
party that actually has standing to pursue a patent invalidity action. Id., cert.
denied, 135 S. Ct. 1401 (2015).
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controversialstem cell patent portfolios is that of the Wiscon-
sin Alumni Research Foundation (WARF).60 WARF is the patent
and licensing arm of the University of Wisconsin-Madison, and
engages in a broad range of research.61 Most of the patents in the
WARF portfolio cover embryonic stem cells, though a large number
apply to stem cells in general.62 The WARF portfolio was involved
in one of the recent cases that was struck down for standing
reasons, so there is little risk of challenge to this portfolio.63
Researcher, professor, and Nobel Prize winner Shinya Yama-
naka also has numerous patents on stem cells, some of which are
highly relevant to adult stem cells.64 Yamanakas research mainly 
focuses on the process to produce iPSCs.65 From this research,
he, along with other scientists and research organizations, has
obtained a number of U.S. patents that focus on that of iPSCs,
as well as a few that cover embryonic stem cells.66 In particular,
60 Brandon Smith, The Patentability ofHuman EmbryonicStem Cells in
Light ofMyriad, 96 J. PAT. & TRADEMARK OFF. SOCY 112, 116 (2014).
61 About Us, WIS. ALUMNI RESEARCH FOUND., http://www.warf.org/about
-us/about-us.cmsx [https://perma.cc/LK5H-ED3X].
62 See Pluripotent Cells: Culture, WIS. ALUMNI RESEARCH FOUND., http://
www.warf.org/technologies/pluripotent-cells/culture.cmsx [https://perma.cc/9GZJ
-KC3X]; Pluripotent Cells: Differentiation, WIS. ALUMNI RESEARCH FOUND.,
http://www.warf.org/technologies/pluripotent-cells/differentiation.cmsx [https://
perma.cc/GY9B-GPBS]; Pluripotent Cells: Related technologies, WIS. ALUMNI
RESEARCH FOUND., http://www.warf.org/technologies/pluripotent-cells/related
-technologies.cmsx [https://perma.cc/7KQ7-PVF5]; Pluripotent Cells: Tools, WIS.
ALUMNI RESEARCH FOUND., http://www.warf.org/technologies/pluripotent-cells
/tools.cmsx [https://perma.cc/PPG4-VP6B].
63 See Consumer Watchdog, 753 F.3d at 1260 (finding that there was no
injury in fact toward the plaintiff to justify standing).
64 See U.S. Patent No. 8,058,065 (filed June 9, 2009); U.S. Patent No.
8,129,187 (filed Feb. 18, 2010); U.S. Patent No. 8,278,104 (filed June 13, 2008).
Yamanaka has patents that relate to embryonic stem cells as well. See U.S.
Patent No. 7,250,255 (filed May 31, 2002); U.S. Patent No. 8,158,766 (filed
July 10, 2006); U.S. Patent No. 8,597,895 (filed Mar. 19, 2012). Yamanakas 
research also extends to uses of stem cells after their creation. See U.S. Patent
No. 8,546,141 (filed Apr. 1, 2009) (describing method for preparing blood cells
from isolated adult stem cells).
65 See, e.g., Kazutoshi Takahashi & Shinya Yamanaka, Induction ofPlu-
ripotent Stem Cells from Mouse Embryonicand Adult Fibroblast Cultures by
Defined Factors, CELL (Aug. 25, 2006), http://www.cell.com/cell/abstract/S00
92-8674(06)00976-7 [https://perma.cc/VWL5-YMRZ].
66 See Smith, supra note 60, at 116.
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U.S. Patent 8,058,065 covers a method to create iPSCs through
reprogramming of the cells nucleus by the induction of certain 
genes into the cells chromosome, and by culturing the cell in 
certain conditions in order to obtain pluripotency.67
All of the patents described herein involved applications that
were filed before the Supreme Court handed down the Myriad
decision. All but one of the patents were granted after the deci-
sion, and that patent was a method patent describing how to
make particularized blood cells from adult stem cells.68 However,
these patents may now be in question after the Myriad decision.
D. The Supreme Courts Decision in Myriad and Its Restriction
on Patents
The Supreme Court directly tackled whether natural prod-
ucts could be patented in the landmark case, Assn for Molecular 
Pathologyv. Myriad Genetics, Inc.69 In this case, Myriad Genetics,
Inc. (Myriad) had created a process for identifying the breast
cancer gene, and had obtained a patent on a complementary
DNA (cDNA) segment.70
The Court first stepped through a scientific breakdown of
how DNA works. Each human genome consists of approximately 
22,000 genes packed into 23 pairs of chromosomes[,] which are 
encoded into a double-helical structure of DNA.71 DNA is broken
up into segments, called nucleotides, which correspond and bond
with another nucleotide on the opposing strand of DNA.72 To-
gether in sequence, these nucleotides code for certain types of
amino acids, which the cell uses to create proteins.73 Importantly,
the nucleotide sequences that actually code for amino acids are
called exons, while sequences of DNA that do not code for amino
acids are called introns.74 Through a complex process of separating
67 U.S. Patent No. 8,058,065 (filed June 13, 2008).
68 U.S. Patent No. 8,546,141 (filed Apr. 1, 2009). Myriad was decided in
June 2013, and the patent was issued in October 2013.
69 133 S. Ct. 2107 (2013).
70 Id. at 2107.
71 Id. at 2111.
72 Id.
73 Id.
74 Id.
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the strands of DNA, transcribing these complementary strands
into complementary RNA, removing introns from the RNA strand,
leaving only exons, and running the RNA through a structure
called a ribosome, amino acids are created, which can form into
proteins essential to cellular function.75
Scientists are able to isolate and extract DNA from cells, and
can also create synthetic DNA that is complementary to the RNA.76
This new DNA is called cDNA.77 Changes in the sequence of DNA
are called mutations, and are heavily studied by scientists.78
This type of research is highly impactful because of the harmful
effects mutations can have on an organisms functionality.79
Myriad discovered the location and DNA sequence of the BRCA1
and BRCA2 genes, mutations of which can increase the risk of
certain types of cancer.80 This discovery was especially im-
portant because [t]he average American woman has a 12 to 13 
percent risk of developing breast cancer, but for women with certain
genetic mutations, the risk can range between 50 and 80 percent
for breast cancer.81
In order to protect its discovery, Myriad applied for and re-
ceived patents, three of which were challenged in this case: U.S.
patents 5,747,282, 5,837,492, and 5,693,473 (the 282 patent, 492 
patent, and 473 patent, respectively).82 From these patents, nine
claims were presented to the Court.83 Claim 1 from the 282 pat-
ent focused on isolated DNA from the BRCA1 gene that coded for
certain amino acids.84 Claim 2 from the 282 patent was similar 
75 Id.
76 Id. at 2112.
77 Id.
78 Id.
79 Id. (Some mutations are harmless, but others can cause disease or in-
crease the risk of disease. As a result, the study of genetics can lead to valuable
medical breakthroughs.). 
80 Id.
81 Id.
82 Id. at 2113; see Assn for Molecular Pathology v. United States Patent & 
Trademark Office, 702 F. Supp. 2d 181, 211 (S.D.N.Y. 2010).
83 Myriad, 133 S. Ct. at 2113 (claims 1, 2, 5, 6, and 7 of the 282 patent, 
claim 1 of the 473 patent, and claims 1, 6, and 7 of the 492 patent). 
84 Id. (The first claim asserts a patent on [a]n isolated DNA coding for a 
BRCA1 polypeptide, which has the amino acid sequence set forth in SEQ ID
NO:2. SEQ ID NO:2 sets forth a list of 1,863 amino acids that the typical 
BRCA1 gene encodes. (citations omitted)). 
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to claim 1, except the sequence was that of the cDNA that Myriad
had developed, and only contained exons, and no introns.85 Claim 5
of the 282 patent covered isolated DNA having at least 15 nu-
cleotides of the DNA of claim 1 that would identify the BRCA1 
gene if searching for specific 15 nucleotide sequences.86 Claim 6
of the 282 patent was similar to claim 5, in that it focused on a 
15 nucleotide sequence of the cDNA referenced in claim 2.87 The
rest of the claims were similar to the previously mentioned
claims, and included references to both the BRCA1 and BRCA2
sequences, as well as common mutations found in the sequences.88
Overall, Myriads patents would have given the company an ex-
clusive right to isolate an individuals BRCA1 and BRCA2 genes 
(or any strand of 15 or more nucleotides within the genes) as well 
as the exclusive right to synthetically create BRCA cDNA.89
In the course of Myriads litigation, the issue that the lower 
courts had struggled with was whether the act of isolating DNA
was actually inventive or simply a product of nature.90 DNA is
held together by chemical bonds, and these bonds must be bro-
ken in order to identify and isolate DNA segments, such as those
that were described in Myriads patents.91
In its analysis, the Court established that it is a long held belief
that the laws of nature are unpatentable.92 The Court explained
that a strong public policy interest requires such a restriction, as
without it, future innovation would be prohibiteda result that 
conflicts with the very purpose of patents, which is to promote
the creation of new inventions.93 However, the Court recognized
that, at a minimal level, all inventions utilize some laws of na-
ture or natural phenomena, so if this exclusion to patentability
85 Id.
86 Id.
87 Id.
88 Id.
89 Id.
90 Id. at 2114.
91 Id.
92 Id. at 2116 (We have long held that [the 35 U.S.C. § 101] provision con-
tains an important implicit exception[:] Laws of nature, natural phenomena,
and abstract ideas are not patentable. (citation omitted)). 
93 Id.; see also Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) ([M]ani-
festations of ... nature[] [are] free to all men and reserved exclusively to none.) 
(internal quotations omitted).
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were broadly interpreted, patent law would destroy itself be-
cause too many patents would be struck down through this prec-
edent.94 What was important for the Court to consider, then,
was whether there was any new and useful ... composition of 
matter, or instead a claim of naturally occurring phenomena.95
Myriad did not make any changes to the genetic information
that was encoded in the genes, nor did it create anything new,
as the gene location and order were already in existence at the
time of Myriads discovery.96 The only potentially patentable
subject matter was the method by which Myriad had discovered
the location and sequence of the genes.97
According to the Court, more is needed than just making an un-
precedented discovery.98 In its patent application, Myriad high-
lighted that locating the gene was the product of extensive research,
and that the company had sorted through millions of pieces of
DNA to discover the genes it was targeting.99 Though Myriad de-
tailed how it searched for these genes, the Court rejected this inves-
tigative process as insufficient to make the DNA patentable.100
The Court also found that simply because Myriad severed the
DNA bonds, it did not automatically create a patentable mole-
cule.101 If Myriad were trying to patent the naturally occurring
genetic sequence, a would-be infringer would simply need to
make a small change at the end of the sequence to avoid any
patent infringement.102
94 Myriad, 133 S. Ct. at 2116.
95 Id. (citing 35 U.S.C. § 101 (2014)).
96 Id.
97 Id.
98 Id. at 2117 (Groundbreaking, innovative, or even brilliant discovery does 
not by itself satisfy the § 101 inquiry.). 
99 Id. (Myriad explains that the location of the gene was unknown until 
Myriad found it among the approximately eight million nucleotide pairs con-
tained in a subpart of chromosome 17.). 
100 Id. at 2118 ([E]xtensive effort alone is insufficient to satisfy the demands 
of § 101.). 
101 Id.
102 Id. (If the patents depended upon the creation of a unique molecule, 
then a would-be infringer could arguably avoid at least Myriads patent claims 
on entire genes ... by isolating a DNA sequence that included both the BRCA1
or BRCA2 gene and one additional nucleotide pair.). 
2016] HARNESSING HUMAN POTENTIAL 871
Myriad asserted that the USPTO had previously allowed for
patents on genetic sequences, and thus their specific code should
be deemed patentable.103 However, the Court rejected this asser-
tion, reasoning that the language of the federal statute does not
mention genes or isolated DNA, and the fact that the USPTO
had previously allowed for genes to be patented does not mean
that all genes must be accepted as patentable.104 Thus, the Court
held that the original pieces of DNA that were claimed as patents
were not patentable.105
However, the Court viewed cDNA differently. cDNA is not a
naturally occurring segment, as the BRCA1 and BRCA2 genes
are.106 There are naturally occurring parts within the cDNA
namely the exons that are still leftbut in nature, these sec-
tions are not readily found.107 Due to its distinguishability from
DNA, this type of cDNA can be patented.108
Interestingly, the Court struck down the notion that it was
invalidating any ability for Myriad or similar companies to claim
a patent over a method of accomplishing gene isolation.109 Myriad
had chosen not to pursue a method patent, however, because the
process of isolating DNA was very commonplace in genetic research
and a person skilled in the art would have already understood how
to accomplish that goal, thus eliminating the requisite novelty.110
In the end, the Court chose to strike down patentability of
regular gene sequences that are naturally found in human cells,
even though they were isolated with human intervention.111 The
103 Id.
104 Id.
105 Id.
106 Id. at 2119 (As already explained, creation of a cDNA sequence from 
mRNA results in an exons-only molecule that is not naturally occurring. Peti-
tioners concede that cDNA differs from natural DNA in that the non-coding 
regions have been removed. (citations omitted)). 
107 Id.
108 Id. (As a result, cDNA is not a product of nature and is patent eligible 
under § 101, except insofar as very short series of DNA may have no inter-
vening introns to remove when creating cDNA.). 
109 Id. (Had Myriad created an innovative method of manipulating genes 
while searching for the BRCA1 and BRCA2 genes, it could possibly have sought
a method patent.). 
110 Id. at 211920. 
111 Id. at 2120.
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Court did allow for the patentability of cDNA, which is not some-
thing found in nature.112
III. THE AFTERMATH OF MYRIAD, BOTH WITHIN THE
USPTO AND THE COURTS
A. The USPTOs Response to Myriad
The day the Supreme Court handed down its ruling in Myriad,
the USPTO issued a narrow guidance to its patent examiners,
explaining that they should now reject product claims drawn
solely to naturally occurring nucleic acids or fragments thereof,
whether isolated or not, as being ineligible subject matter under
35 U.S.C. § 101.113 The memorandum did not mention the
broader holding excluding all natural products, and instead
pointed examiners to MPEP 2106 to determine if the subject
matter is patentable.114
In March of 2014, the USPTO put out its official guidance re-
garding new procedures for subject matter eligibility in light of
Myriad and Mayo (the Guidance).115 The Guidance expanded
on the previous memorandum, and now stated that all claims ... 
reciting or involving laws of nature/natural principles, natural
phenomena, and/or natural products require a marked differ-
ence from nature; otherwise, the application should be rejected.116
The Guidance first speaks to the overall process of subject
matter eligibility under 35 U.S.C. § 101.117 The USPTO breaks
down the process into three main steps: (1) whether the claim is
directed to one of the four statutory categories of process
machine, manufacture, or composition of matter; (2) whether the
claim recites or involves potential judicial exceptionsabstract 
ideas, laws of nature, natural phenomena, or natural products;
112 Id. at 2119.
113 U.S. Patent and Trademark Office, Memorandum on Supreme Court
Decision in Association for Molecular Pathologyv. Myriad Genetics, Inc. to Patent
Examining Corps (June 12, 2013), http://www.uspto.gov/sites/default/files
/patents/law/exam/myriad_20130613.pdf.
114 Id. (Other claims, including method claims, that involve naturally oc-
curring nucleic acids may give rise to eligibility issues. (emphasis added)). 
115 USPTO Guidance, supra note 4.
116 Id. at 1.
117 Id. at 2.
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and (3) whether the claim recites something significantly differ-
ent than the exception.118 This last requirement can be the most
unclear, so the USPTO provides guidelines on how to interpret
whether something is significantly different.119 Specifically, the
USPTO provides six factors for a claim to weigh toward eligibility:
(a) Claim is a product claim reciting something that initially
appears to be a natural product, but after analysis is deter-
mined to be non-naturally occurring and markedly different in
structure from naturally occurring products.
(b) Claim recites elements/steps in addition to the judicial ex-
ception(s) that impose meaningful limits on claim scope, i.e., the
elements/steps narrow the scope of the claim so that others are
not substantially foreclosed from using the judicial exception(s).
(c) Claim recites elements/steps in addition to the judicial ex-
ception(s) that relate to the judicial exception in a significant
way, i.e., the elements/steps are more than nominally, insig-
nificantly, or tangentially related to the judicial exception(s).
(d) Claim recites elements/steps in addition to the judicial ex-
ception(s) that do more than describe the judicial exception(s) with
general instructions to apply or use the judicial exception(s).
(e) Claim recites elements/steps in addition to the judicial ex-
ception(s) that include a particular machine or transformation
of a particular article, where the particular machine/transforma-
tion implements one or more judicial exception(s) or integrates
the judicial exception(s) into a particular practical application.
(f) Claim recites one or more elements/steps in addition to the
judicial exception(s) that add a feature that is more than well-
understood, purely conventional or routine in the relevant field.120
In addition to these positive factors that weigh towards patent-
ability, the Guidance recites inverse factors that weigh against
patentability because the claim is not significantly different from
nature.121
118 Id.
119 Id. at 35. 
120 Id. at 4.
121 Id. at 45. Items (g) through (l) weigh against patentability and are nearly 
the same as those listed in (a) through (f). However, the requirements are re-
versed to show the item is not significantly different. For example, factor (a)
states that a product claim may initially look like a natural product, but after
further analysis it is determined to be non-naturally occurring and markedly
different from a natural product. Item (g) inversely provides that a product
claim may look like a natural product, which is not markedly different from a
naturally occurring product. Id.
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Importantly, the USPTO provides that a material or process
may still be patent-eligible, even if a natural process was affected by
human intervention, as long as there is a marked difference be-
tween the resulting product and the product occurring in nature.122
This statement is significant concerning the production of iPSCs: if
human stem cells are considered to be a natural product or a mate-
rial produced by a natural process, the human intervention that
produces an unnatural pluripotency creates a presumption that the
method and the iPSCs product must be considered patentable.123
The Guidance is helpful in providing examples of situations
where a certain product or process may be considered patent-
able.124 Though none of the examples speak to stem cells specifi-
cally, some do address the significant difference that an induced
pluripotent adult stem cell would demonstrate.125
Though the USPTOs Guidance provided some instruction 
about how to approach the Myriad decision, courts have yet to
apply the decision. The USPTO also has yet to issue its updated
guidance on how patent examiners are to incorporate Myriad
into their examinations. Most importantly, the USPTO provided
no guidance on how examiners and the courts should view the
patentability of stem cells.
B. Court Response After Myriad and the Updated USPTO
Guidance
At the time of the writing of this Note, there have been fewer
than thirty recorded court decisions that have cited to Myriad
122 Id. (The fact that a marked difference came about as a result of rou-
tine activity or via human manipulation of natural processes does not prevent
the marked difference from weighing in favor of patent eligibility.). 
123 Assn for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 
2119 (2013) (stating that although the isolated DNA was not considered patent-
able subject matter, an innovative process to isolate the DNA could be a patent-
able method); see also Diamond v. Chakrabarty, 447 U.S. 303, 30910 (1980) 
(extending patentability to a nonnaturally occurring manufacture or compo-
sition of mattera product of human ingenuity having a distinctive name, 
character [and] use.) (quoting Hartranft v. Wiegmann, 121 U.S. 609, 615 (1887)).
124 USPTO Guidance, supra note 4, at 518. 
125 Id. at 5. The USPTO finds that a simple plasmid is not significantly
different from a naturally occurring substance, while the engineered bacterium
containing the plasmid can be considered significantly different from what is
found in nature. Id.
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when considering patentability cases, and some of those cases
have not been decided based on the analysis of the patentability
of the claims at issue.126
Some cases, however, have directly concerned patentability of
natural products. In the Federal Circuits case In re Roslin Insti-
tute (Edinburgh), patents involved in mammalian cloning were
at issue.127 The patent holders had obtained patents over the
method to clone Dolly, the famous sheep,128 and filed a patent
application covering the clones resulting from that method.129
The method patent was not at issue, but the patent application
for the clones was.130 The challengers to the patent application,
with whom the Patent Trials and Appeals Board agreed, argued
that the claimed subject matter was simply a natural phenome-
non that did not possess any marked difference from that found
in nature.131 The court agreed, and rejected the patent appli-
cants assertion that the mammalian copies could not be found
in nature and required human intervention to come into being,
thus allowing the claims to fall under patentable subject mat-
ter.132 Citing Myriad, the court found that the patent holder did
not alter the genes found in the clones, but used exact copies;
therefore, the clones were not patentable.133
Although the method patent was not at issue in that case, In
re Roslin Institute has implications for how stem cell patents
may be interpreted in the Federal Circuit, the main court that
126 See, e.g., Consumer Watchdog v. Wis. Alumni Research Found., 753
F.3d 1258 (Fed. Cir. 2014) (dismissing Consumer Watchdogs claims due to 
lack of standing).
127 750 F.3d 1333 (Fed. Cir. 2014).
128 John Whitfield, Obituary: Dolly the Sheep, NATURE (Feb. 18, 2003),
http://www.nature.com/news/1998/030217/full/news030217-6.html [https://perma
.cc/8GLR-4P4Z].
129 In re Roslin Inst., 750 F.3d 1333, 133435 (Fed. Cir. 2014). 
130 Id. at 1334.
131 Id. at 1335.
132 Id. at 1337.
133 Id. (Here, as in Myriad, Roslin did not create or alter any of the 
genetic information of its claimed clones, [n]or did [Roslin] create or alter the 
genetic structure of [the] DNA used to make its clones. Instead, Roslins chief 
innovation was the preservation of the donor DNA such that the clone is an
exact copy of the mammal from which the somatic cell was taken. Such a copy
is not eligible for patent protection. (citing Assn for Molecular Pathology v. 
Myriad Genetics, Inc., 133 S. Ct. 2107, 2111 (2013))).
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hears patent appeals.134 Stem cells may have the same genetic
makeup as that of a predecessor, and are simply induced into
differentiation or proliferation through external factors.135 This
would likely be covered in a method patent. In re Roslin Institute
suggests that an exact copy is not likely to be patentable.136
However, a resulting cell or organism that has the same genetic
DNA as a naturally occurring predecessor does not necessarily
disqualify the subject matter from being patentable.137
Furthermore, some adult stem cell patents require an inser-
tion of specific genes in order to induce the stem cell to proliferate
and develop pluripotency.138 The insertion of new genes non-
existent in the original cell would create an organism that is
markedly different from the naturally occurring cell, and under
Myriad, preceding cases like Chakrabarty, and the updated
MPEP, this new subject matter would be considered patent-
able.139 As the Supreme Court pointed out in Myriad, method
patents are available for inventors who come up with novel ways
to produce a material.140 At the very minimum, inventors must
be able to patent novel processes that create iPSCs, assuming
that the processes are not natural processes as well. The other
cases adjudicated by the Federal Circuit did not involve much
analysis into how Myriadapplies to the issues before them.141
134 U.S. COURT OF APPEALS FOR THE FED. CIRCUIT, COURT JURISDICTION,
http://www.cafc.uscourts.gov/the-court/court-jurisdiction [https://perma.cc/TS4G
-H23U]. The Federal Circuit was formed by the merging of the United States
Court of Customs and Patent Appeals with the appellate division of the United
States Court of Claims. The court also takes direct appeals from the Patent
Trial and Appeal Board.
135 See supra Part I.
136 In re Roslin Inst., 750 F.3d at 1339.
137 Id. ([H]aving the same nuclear DNA as the donor mammal may not
necessarily result in patent ineligibility in every case.); see also USPTO
Guidance, supra note 4, at 4. Factor (a) in the Guidance allows patentability
for subject matter that appears on its face to be naturally occurring, i.e., has
the same genetic makeup as a predecessor and can still be shown to be markedly
different in structure or function. Id.
138 See U.S. Patent No. 8,058,065 (filed June 9, 2009) (patent claims cover the
induction of retroviral vectors, which insert genes into the target cell DNA).
139 See Assn for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct.
2107, 2109 (2013); Diamond v. Chakrabarty, 447 U.S. 303, 310 (1980).
140 Myriad, 133 S. Ct. at 2119.
141 See Consumer Watchdog v. Wis. Alumni Research Found., 753 F.3d
1258 (Fed. Cir. 2014); In re Bentwich, 566 Fed. Appx. 941, 943 (Fed. Cir. 2014) 
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Other courts have taken different approaches to Myriad. In
an interesting development, two separate district courts review-
ing the same patent returned different verdicts after deeply ana-
lyzing the patent at issue.142 The patent in contention was a
method for amplifying DNA.143 The plaintiff filed six suits in
different district courts,144 but its motion for centralization of the
claims was denied,145 even though the motion alleged that vari-
ous companies had infringed on its patent.146 The District Court
of Delaware ruled that the method was so closely tied to natural
laws that it could not be found to be patentable, and thus granted
the defendants motion to dismiss that claim.147 Conversely, the
Northern District of California found that the claim was valid be-
cause the defendant could not show with clear and convincing evi-
dence that the patent claims were mere applications of natural
laws.148 Ironically, the Multidistrict Litigation Judicial Panel that
had denied centralization of the claims expressly hoped that this
type of result would not occur.149
CONCLUSION
When Myriad was defending its patents in front of the Su-
preme Court, the company faced opposition from many amicus
(patent applicant already conceded that the claimed product at issue, a viral
nucleic acid, was naturally occurring, and thus the court made no ruling on how
Myriad applied to the claim).
142 Genetic Techs. Ltd. v. Agilent Techs., Inc., 24 F. Supp. 3d 922 (N.D.
Cal. 2014); see also Genetic Techs. Ltd. v. Bristol-Myers Squibb Co., 72 F. Supp.
3d 521 (D. Del. 2014).
143 Bristol-Myers SquibbCo., 72 F. Supp. 3d at 521.
144 Agilent Techs., Inc., 24 F. Supp. 3d at 925; see also Bristol-Myers Squibb
Co., 72 F. Supp. 3d at 52324. 
145 In re Genetic Techs. Ltd. (179) Patent Litig., 883 F. Supp. 2d 1337, 1338 
(J.P.M.L. 2012) (denying centralization of venue for the patent infringement
claim against the six defendants in four different venues).
146 Agilent Techs., Inc., 24 F. Supp. 3d at 925; see also Bristol-Myers Squibb
Co., 72 F. Supp. 3d at 52324. 
147 Bristol-Myers SquibbCo., 72 F. Supp. 3d at 523.
148 Agilent Techs., Inc., 24 F. Supp. 3d at 931.
149 In re Genetic Techs. Ltd. (179) Patent Litig., 883 F. Supp. 2d at 1338 
(Though we are denying centralization, we nevertheless encourage the parties 
and involved courts to pursue various alternative approaches, should the
need arise, to minimize the potential for ... inconsistent pretrial rulings.). 
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curiae briefs.150 The argument that pervaded many of these ami-
cus briefs alleged that patents like Myriads restrict innovation 
in important areas like cancer research, and extend the timeline
of treatment development.151 Although keeping an eye on the
public interest is important for all areas of the law, patent law
specifically addresses the public interest when considering the
patent bargain.152 The idea behind the patent bargain is that the
public wants to induce inventors to tell us about their inventions
and, in exchange, we give them a period of exclusivity for that
specific invention.153 The patent bargain is a foundation of the
Intellectual Property Clause in the Constitution,154 and was impor-
tant to Thomas Jefferson in his consideration of how patents should
be treated in the United States.155
Of course, patents should not be given to inventors whose in-
ventions do not meet the criteria of patentability. But if an inven-
tor does create a novel, useful, and non-obvious invention, and
meets the other factors of patentability required by the USPTO
or the statute, then she is entitled to receive a patent that ex-
cludes others from making, selling, and using the invention for a
limited time. Myriad had created something patentable in its
cDNA invention, and has the right to exclude others for uses of
this invention.156 In return, Myriad disclosed what the invention
was, including the best mode for a person skilled in the art to
create the invention.157
150 See, e.g., Brief for Am. Med. Assn et al. as Amici Curiae Supporting Peti-
tioners, Assn for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107 
(2013) (No. 12-398).
151 See id. at 10.
152 35 U.S.C. § 2(a)(2), § 2(b)(2)(E) (2012).
153 Kevin E. Mohr, At the Interface ofPatent and TrademarkLaw: Should
A Product Configuration Disclosed In A UtilityPatent Ever QualifyFor Trade
Dress Protection?, 19 HASTINGS COMM. & ENT. L.J. 339, 344 (1997).
154 U.S. CONST. art. I, § 8, cl. 8.
155 Letter from Thomas Jefferson to Isaac McPherson (Aug. 13, 1813), in 13
THE WRITINGS OF THOMAS JEFFERSON 32627, 334 (Albert Ellery Bergh ed., 
1907) (An inventor has no right to obstruct others in the use of what they 
possessed before. Jefferson later states that [s]ociety may give an exclusive 
right to the profits arising from [inventions], as an encouragement to men to
pursue ideas which may produce utility, but this may or may not be done, ac-
cording to the will and convenience of the society, without claim or complaint
from anybody.). 
156 See supra note 108 and accompanying text.
157 See U.S. Patent No. 5,747,282 (filed June 7, 1995).
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Adult stem cells and methods for creating stem cells are ex-
tremely important for the future of scientific research. Many dif-
ferent types of important adult stem cell therapies are currently
undergoing extensive research. Such innovative research is not
the only reason adult stem cells should be used; ethical concerns
surrounding embryonic stem cell research can cause public out-
cry or potential reduction in government funding,158 and thus
research using adult stem cells instead can quell these issues.
To incentivize this forward-thinking and ethical research, inven-
tors should receive patent protection for taking novel approaches
to developing both adult stem cells and methods for inducing adult
stem cells that do not naturally occur. Patent protection should
be afforded because adult stem cells are likened to the bacteria
found in Chakrabarty.159 Although the initial adult stem cells are
found in nature (like the bacteria in Chakrabarty), the final prod-
uct can be something that would never actually occur on its
own.160 This is markedly different from the isolated DNA in Myriad.
Adult stem cells are not merely isolated from their environment.
Instead, they are transformed into completely new material. This
type of research should be encouraged by the public, and patent
protection should incentivize these researchers to devote time and
money to creating such landmark therapies. Though embryonic
stem cells present problems regarding achieving patentability,
adult stem cells and the methods to create them are different
enough from nature to allow for patent protection.
158 See Gilbert, supra note 13.
159 See STEM CELL BASICS VI, supra note 5; Diamond v. Chakrabarty, 447
U.S. 303, 305 (1980).
160 See STEM CELL BASICS VI, supra note 5.

